MDT

89.47

+0.29%↑

VEEV

279.53

-0.5%↓

A

113.32

-3.16%↓

WBA

11.5

-0.09%↓

HQY

96.34

-1.04%↓

MDT

89.47

+0.29%↑

VEEV

279.53

-0.5%↓

A

113.32

-3.16%↓

WBA

11.5

-0.09%↓

HQY

96.34

-1.04%↓

MDT

89.47

+0.29%↑

VEEV

279.53

-0.5%↓

A

113.32

-3.16%↓

WBA

11.5

-0.09%↓

HQY

96.34

-1.04%↓

MDT

89.47

+0.29%↑

VEEV

279.53

-0.5%↓

A

113.32

-3.16%↓

WBA

11.5

-0.09%↓

HQY

96.34

-1.04%↓

MDT

89.47

+0.29%↑

VEEV

279.53

-0.5%↓

A

113.32

-3.16%↓

WBA

11.5

-0.09%↓

HQY

96.34

-1.04%↓

Search

ESPERION THERAPEUTICS INC

Geschlossen

BrancheGesundheitswesen

1.12 -5.08

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.12

Max

1.19

Schlüsselkennzahlen

By Trading Economics

Einkommen

-19M

-40M

Verkäufe

-4.1M

65M

EPS

-0.206

Gewinnspanne

-62.243

Angestellte

304

EBITDA

-16M

-21M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+439.83% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

11. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

74M

232M

Vorheriger Eröffnungskurs

6.2

Vorheriger Schlusskurs

1.12

Nachrichtenstimmung

By Acuity

100%

0%

359 / 376 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

ESPERION THERAPEUTICS INC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Juli 2025, 23:41 UTC

Market Talk

Nikkei May Trade in Range Amid Tariff Uncertainty -- Market Talk

15. Juli 2025, 23:40 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

15. Juli 2025, 23:05 UTC

Market Talk

Auckland International Airport Passenger Growth May Disappoint Again -- Market Talk

15. Juli 2025, 21:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Juli 2025, 21:36 UTC

Market Talk

Canada CPI Data Fuel Rate-Prediction Revisions -- Market Talk

15. Juli 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

15. Juli 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Juli 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

15. Juli 2025, 20:14 UTC

Akquisitionen, Fusionen, Übernahmen

Chinese EV Makers to Combine. Geely Is Buying Zeekr. -- Barrons.com

15. Juli 2025, 20:07 UTC

Ergebnisse

BlackRock Shares Tumble After Big Client Redemption Blunts Quarterly Results -- Update

15. Juli 2025, 20:06 UTC

Market Talk

Nvidia, AMD Seen Benefiting from Return to Chinese Chip Sales -- Market Talk

15. Juli 2025, 19:54 UTC

Market Talk

Global Equities Roundup: Market Talk

15. Juli 2025, 19:54 UTC

Market Talk

Meta CEO Hints at Higher Revenues, Expenses With Data Center Plans -- Market Talk

15. Juli 2025, 19:38 UTC

Market Talk

Oil Falls As Eventual Oversupply Concerns Weigh -- Market Talk

15. Juli 2025, 19:09 UTC

Market Talk

U.S. Natural Gas Futures Post Back-to-Back Gains -- Market Talk

15. Juli 2025, 19:07 UTC

Market Talk

Canada CFOs Willing to Take Risks, Increase Spending -- Market Talk

15. Juli 2025, 19:03 UTC

Market Talk

Gold Slips as Big Buyers Pull Back -- Market Talk

15. Juli 2025, 18:32 UTC

Akquisitionen, Fusionen, Übernahmen

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15. Juli 2025, 18:31 UTC

Akquisitionen, Fusionen, Übernahmen

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

15. Juli 2025, 18:13 UTC

Market Talk

Canada Adopts 'Note of Realism' in US Trade Talks, Setting Stage for Possible Tariff Deal -- Market Talk

15. Juli 2025, 17:40 UTC

Market Talk

Canadian Inflation Adds to Case for Bank of Canada Extending Pause -- Market Talk

15. Juli 2025, 17:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Juli 2025, 17:25 UTC

Akquisitionen, Fusionen, Übernahmen

National Fuel Gas Gets Rare Double Upgrade. Buy the Stock, Analyst Says. -- Barrons.com

15. Juli 2025, 17:24 UTC

Market Talk

Dollar Gains Strength After Inflation Data -- Market Talk

15. Juli 2025, 16:49 UTC

Market Talk

Oil Futures Likely to Continue Sideways Trade -- Market Talk

15. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

15. Juli 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Juli 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

15. Juli 2025, 15:42 UTC

Market Talk

Coca-Cola Seen as Top Pick Ahead of Consumer Staples Earnings -- Market Talk

Peer-Vergleich

Kursveränderung

ESPERION THERAPEUTICS INC Prognose

Kursziel

By TipRanks

439.83% Vorteil

12-Monats-Prognose

Durchschnitt 6.37 USD  439.83%

Hoch 16 USD

Tief 1.85 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für ESPERION THERAPEUTICS INC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

3

Buy

1

Halten

1

Sell

Technischer Score

By Trading Central

0.85 / 1.05Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

359 / 376 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.